Mesenchymal stem cell (MSC)–based tissue regeneration therapy has been extensively investigated for cardiac regeneration over the past two decades. Numerous animal and clinical investigations demonstrated the efficacy of various types of MSCs towards myocardial protection and restoration against anthracycline-induced cardiotoxicity (AIC). It has been established that local or systemic administration of MSCs considerably improved the cardiac function, while ameliorating inflammatory responses and myocardial fibrosis. Several factors influence the outcomes of MSC treatment for AIC, including MSC types, dosages, and routes and duration of administration. In this review, we discuss the recent (from 2015 to 2020) experimental and clinical research on the preventive and regeneration efficacy of different types of MSCs (with or without supporting agents) against AIC, as well as the key factors responsible for MSC-mediated cardiac repair. In addition, challenges and future perspectives of MSC-based cardiac regeneration therapy are also outlined.

中文翻译：

---

间充质干细胞在蒽环类药物诱导的心脏毒性中的新兴治疗作用

在过去的二十年中，基于间充质干细胞 (MSC) 的组织再生疗法已被广泛研究用于心脏再生。许多动物和临床研究证明了各种类型的间充质干细胞对心肌保护和恢复对抗蒽环类药物引起的心脏毒性 (AIC) 的功效。已经确定局部或全身施用 MSC 可显着改善心脏功能，同时改善炎症反应和心肌纤维化。有几个因素会影响 MSC 治疗 AIC 的结果，包括 MSC 类型、剂量、给药途径和持续时间。在这次审查中，我们讨论了最近（2015 年至 2020 年）关于不同类型 MSCs（有或没有支持剂）对 AIC 的预防和再生功效的实验和临床研究，以及负责 MSC 介导的心脏修复的关键因素。此外，还概述了基于 MSC 的心脏再生治疗的挑战和未来前景。